$凡利亚药品国际(VRX)$ ：市场之前对VRX的新药几乎没有反应实在有些过分。希望VRX回归只是刚刚开始。

"So why are we excited about VYZULTA? Because globally, glaucoma is a large market opportunity and expected to grow at a CAGR of 15% over the next four-year period. As the first novel treatment in two decades, we believe there is a great opportunity for VYZULTA." Joe on VYZULTA